Form 4: Axogen's Chief Innovation Officer Receives 38,000 Restricted Stock Units

Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., reports the acquisition of 38,000 restricted stock units (RSUs) on March 25, 2025, vesting over a four-year period.

Summary

• Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 25, 2025.
• DeVinney acquired 38,000 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of Axogen, Inc. common stock per unit.
• The RSUs will vest over four years, with 50% vesting on March 25, 2027, and an additional 25% vesting each 12 months thereafter until March 25, 2029.
• Vested shares will be delivered to DeVinney upon the vesting date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.

Future Outlook

The vesting schedule of the restricted stock units suggests a commitment to the company's long-term performance by the Chief Innovation Officer.

Industry Context

Grants of restricted stock units are a common practice in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, particularly in the biotech sector.
• Companies like Stryker, Medtronic, and Boston Scientific also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of four years is fairly standard, aligning with typical long-term incentive plans.

Stakeholder Impact

• The grant of RSUs could have a slightly dilutive effect on existing shareholders, but it also incentivizes management to increase shareholder value.

Key Dates

Keywords

Axogen, Restricted Stock Units, Form 4, Erick DeVinney, Chief Innovation Officer, AXGN, SEC Filing